Skip to main content

Table 1 Subjects’ baseline characteristics

From: Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial

 

Placebo (n = 10) Mean ± SD

95% CI

Curcumin (n = 9) Mean ± SD

95% CI

Age (years)

38.1 ± 11.1

30.1;46.1

32.7 ± 12.3

23.1;42.1

Height (cm)

174.8 ± 3.0

172.7;176.9

176.6 ± 3.6

173.7;179.4

Weight (kg)

75.8 ± 6.5

71.2;80.4

76.2 ± 4.2

73.0;79.5

BMI (kg/m2)

24.8 ± 1.7

23.6;26.0

24.4 ± 1.0

23.6;25.2

VO2/kg (ml/kg)

45.8 ± 4.7

42.5;49.2

48.9 ± 5.3

44.8;53.1

Maximal speed (maximal exercise test) (km/h)

13.7 ± 1.8

12.4;15.0

14.8 ± 1.1

13.9:15.6

Speed at the anaerobic threshold (km/h)

10.9 ± 1.7

6.6;12.1

11.8 ± 1.5

10.6;12.9

Speed during the injury provocation test (km/h)

10.9 ± 1.2

10.0;11.7

11.4 ± 0.9

10.8;11.4